IKT INHIBIKASE THERAPEUTICS INC Capital Structure Changes 8-K Filing 2024 - ATM Agreement Termination Inhibikase Therapeutics terminated its At the Market Offering Agreement, which allowed it to sell up to $5,659,255 in common stock, after selling 315,338 shares for $849,187.85; the maximum offering price was later reduced to $50,000 before termination.Get access to all SEC 8-K filings of the INHIBIKASE THERAPEUTICS INC